Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Market Closed 05-08 16:00:00 EDT

81.89

-1.48

-1.78%

盘后81.00

-0.89-1.09%

19:26 EDT

High84.94	Low80.91	Vol722.77K
Open84.94	D1 Closing83.37	Amplitude4.83%
Mkt Cap2.76B	Tradable Cap2.42B	Total Shares33.74M
T/O59.21M	T/O Rate2.45%	Tradable Shares29.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":81.89,"timestamp":1778270400000,"preClose":83.37,"halted":0,"volume":722769,"hourTrading":{"tag":"盘后","latestPrice":81,"preClose":81.89,"latestTime":"19:26 EDT","volume":8125,"amount":663264.67,"timestamp":1778282787390,"change":-0.89,"changeRate":-0.010868,"amplitude":0.024179},"delay":0,"changeRate":-0.017752189036823844,"floatShares":29514600,"shares":33742100,"eps":-9.73,"marketStatus":"Market Closed","change":-1.48,"latestTime":"05-08 16:00:00 EDT","open":84.94,"high":84.94,"low":80.91,"amount":59208838.957049996,"amplitude":0.048339,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.73,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778486400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":83.37,"preHourTrading":{"tag":"盘前","latestPrice":84,"preClose":83.37,"latestTime":"09:25 EDT","volume":1051,"amount":87118.17825,"timestamp":1778246700052,"change":0.63,"changeRate":0.007557,"amplitude":0.047379},"postHourTrading":{"tag":"盘后","latestPrice":81,"preClose":81.89,"latestTime":"19:26 EDT","volume":8125,"amount":663264.67,"timestamp":1778282787390,"change":-0.89,"changeRate":-0.010868,"amplitude":0.024179},"volumeRatio":1.0725709503436889,"impliedVol":0.4051,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/NKTR/wiki","defaultTab":"wiki","newsList":[{"id":"2634495413","title":"Nektar Therapeutics Charts Aggressive Path With REZPEG","url":"https://stock-news.laohu8.com/highlight/detail?id=2634495413","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634495413?lang=en_us&edition=fundamental","pubTime":"2026-05-09 08:51","pubTimestamp":1778287866,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (($NKTR)) has held its Q1 earnings call. Read on for the main highlights of the call. Nektar Therapeutics’ latest earnings call...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-charts-aggressive-path-with-rezpeg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-charts-aggressive-path-with-rezpeg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634498307","title":"Nektar Therapeutics Establishes New Equity Distribution Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634498307","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634498307?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:21","pubTimestamp":1778278902,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics ( ($NKTR) ) has issued an update. On May 8, 2026, Nektar Therapeutics entered into an equity distribution agreement with Guggen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-establishes-new-equity-distribution-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-establishes-new-equity-distribution-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","EQD","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634295460","title":"Nektar Therapeutics Names Rubinstein New Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2634295460","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634295460?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:20","pubTimestamp":1778278800,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics named Linda Rubinstein as its next interim chief financial officer, effective May 15.Rubinstein, a partner of CFO services firm FLG Partners, succeeds Sandra Gardiner, who was also CFO on an interim basis and is a partner at FLG, according to a Friday filing with the Securities and Exchange Commission.Gardiner will be retiring and stepping down from the position at Nektar, which she has held since 2023, Nektar said.Rubinstein has been permanent and interim CFO of several public and private companies including Adverum Biotechnologies, Diasome, Five Prime, Ingenuity, iPierian, Kezar, and Tunitas.Nektar also said it entered an amendment to its consulting agreement with FLG, under which it will pay FLG $650 per hour for Rubinstein's services.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634467727","title":"BRIEF-Nektar Therapeutics May Offer And Sell Common Stock Up To $150 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2634467727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634467727?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:27","pubTimestamp":1778275660,"startTime":"0","endTime":"0","summary":"BRIEF-Nektar Therapeutics May Offer And Sell Common Stock Up To $150 Million - SEC FilingMay 8  - Nektar Therapeutics NKTR.O:NEKTAR THERAPEUTICS - ENTERS EQUITY DISTRIBUTION AGREEMENT WITH GUGGENHEIM SECURITIES AND H.C. WAINWRIGHT  CO. - SEC FILINGNEKTAR THERAPEUTICS - MAY OFFER AND SELL COMMON STOCK UP TO $150 MILLION - SEC FILINGSource text: [ID:n0001193125-26-215065]Further company coverage: NKTR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L1G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634902467","title":"Nektar Therapeutics - to Offer up to $150 Mln in Common Stock via Equity Distribution Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2634902467","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634902467?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:12","pubTimestamp":1778274773,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L1WD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634467187","title":"Nektar Therapeutics - Sandra Gardiner to Retire as Interim CFO Effective May 15, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2634467187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634467187?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:12","pubTimestamp":1778274773,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L1WD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634671834","title":"Nektar enters equity distribution deal for up to $150 million at-the-market offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2634671834","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634671834?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:12","pubTimestamp":1778274725,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics entered an equity distribution agreement to sell up to USD 150 million of common stock in an at-the-market offering.Guggenheim Securities and H.C. Wainwright will act as sales agents, with shares sold from time to time at market prices, prices tied to prevailing market levels, or negotiated prices.Sales are optional, with either side able to suspend or terminate the offering on notice.Agents will receive a 3% commission on gross proceeds from any shares sold.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission ,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL8HNfkp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633450051","title":"Nektar Therapeutics Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633450051?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:19","pubTimestamp":1778253540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 11:19 ET (15:19 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633582614","title":"Nektar price target raised to $192 from $105 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633582614","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633582614?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:17","pubTimestamp":1778239040,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Nektar (NKTR) to $192 from $105 and keeps an Overweight rating on the shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-price-target-raised-to-192-from-105-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-price-target-raised-to-192-from-105-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633610660","title":"Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2633610660","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633610660?lang=en_us&edition=fundamental","pubTime":"2026-05-08 07:35","pubTimestamp":1778196928,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh has reiterated their bullish stance on NKTR stock, giving a Buy rating on April 21. Andy Hsieh has given his Buy r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nektar-therapeutics-strong-cash-position-and-late‑stage-autoimmune-pipeline-underpin-attractive-risk‑reward-and-outperform-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nektar-therapeutics-strong-cash-position-and-late‑stage-autoimmune-pipeline-underpin-attractive-risk‑reward-and-outperform-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","SSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141177","title":"Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141177","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141177?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:52","pubTimestamp":1778187177,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $10.86M, consensus $10.69M. “2026 is shaping up to be a defining year for Nektar (NKTR) and for our lead biologic candidate rezp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-reports-q1-adjusted-eps-1-82-consensus-1-48-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-reports-q1-adjusted-eps-1-82-consensus-1-48-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633117410","title":"Nektar Therapeutics Q1 net loss narrows on lower G&A costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633117410","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633117410?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:31","pubTimestamp":1778185864,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics Q1 net loss narrows on lower G&A costsOverviewUS biotech firm's Q1 revenue rose slightly yr/yr, net loss narrowedOperating expenses fell due to lower G&A costs, offset by higher R&","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K1PN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633313171","title":"Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633313171","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633313171?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:16","pubTimestamp":1778185010,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(1.62) by 12.35 percent. This is a 49.72 percent increase over losses of $(3.62) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52389611/nektar-therapeutics-q1-eps-1-82-misses-1-62-estimate-sales-10-860m-beat-10-636m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171800","title":"BRIEF-Nektar Therapeutics Q1 EPS USD -1.82","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171800","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171800?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:15","pubTimestamp":1778184950,"startTime":"0","endTime":"0","summary":"BRIEF-Nektar Therapeutics Q1 EPS USD -1.82\n\n\nMay 07 (Reuters) - Nektar Therapeutics Q1 net income USD -44.904 million.\n\nQ1 product sales USD 10.861 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX22880E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633790351","title":"Nektar Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633790351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633790351?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:15","pubTimestamp":1778184904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA19WS2M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632660990","title":"A Look At Nektar Therapeutics (NKTR) Valuation After New REZOLVE AA Data Funding And Phase 3 Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2632660990","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632660990?lang=en_us&edition=fundamental","pubTime":"2026-05-03 13:33","pubTimestamp":1777786405,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) recently reported 52-week Phase 2b REZOLVE-AA data for rezpegaldesleukin in severe alopecia areata, alongside US$699 million of fresh funding and plans to move the program into Phase 3 trials.\nSee our latest analysis for Nektar Therapeutics.\nNektar’s share price has swung sharply over the past year, with a 30 day share price return of 12.30% and a 90 day share price return of 126.81%, while the 1 year total shareholder return is very large, alongside fresh REZOLVE...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-after-new-rezol","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/a-look-at-nektar-therapeutics-nktr-valuation-after-new-rezol","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4585","NKTR","LU2543165471.USD","BK4153","BK4007","AA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632384640","title":"Nektar Therapeutics grants inducement equity awards to new hires under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2632384640","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632384640?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:40","pubTimestamp":1777668034,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics granted inducement equity awards on April 20, 2026 to six newly hired employees under its 2025 Inducement Plan.Awards comprised non-qualified stock options covering 28,450 shares plus 2,950 restricted stock units.Options carry an exercise price of $100.35 per share.Equity awards vest over four years, subject to continued employment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL4Grdky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632809640","title":"Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632809640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632809640?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:40","pubTimestamp":1777668016,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nTUA7SSHFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115437258","title":"Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to decrease by 30.74%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1115437258","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115437258?lang=en_us&edition=fundamental","pubTime":"2026-05-01 03:01","pubTimestamp":1777575681,"startTime":"0","endTime":"0","summary":"Abstract Nektar Therapeutics is scheduled to report its quarterly results on May 7, 2026 Post Market, with investor attention on revenue near 10.64 million US dollars, losses moderating on a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to decrease by 30.74%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631534448","title":"Nektar to report first-quarter results after US markets close, host conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2631534448","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631534448?lang=en_us&edition=fundamental","pubTime":"2026-04-29 06:00","pubTimestamp":1777413617,"startTime":"0","endTime":"0","summary":"Nektar schedules first-quarter financial results release for May 7, 2026.Conference call set for May 7, 2026, 5:00 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLb6XhCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0529},{"period":"1month","weight":0.0907},{"period":"3month","weight":1.2247},{"period":"6month","weight":0.4631},{"period":"1year","weight":7.821},{"period":"ytd","weight":0.9368}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.016904},{"month":5,"riseRate":0.34375,"avgChangeRate":0.001852},{"month":6,"riseRate":0.40625,"avgChangeRate":0.024924},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.019557},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}